Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dronabinol | 9 | 2019 | 30 | 3.020 |
Why?
|
| Memory, Short-Term | 6 | 2019 | 140 | 2.290 |
Why?
|
| Cocaine | 6 | 2019 | 207 | 1.230 |
Why?
|
| Guanfacine | 2 | 2019 | 7 | 1.220 |
Why?
|
| Cocaine-Related Disorders | 7 | 2019 | 203 | 1.150 |
Why?
|
| Prefrontal Cortex | 12 | 2013 | 184 | 1.090 |
Why?
|
| Memory Disorders | 2 | 2019 | 236 | 1.020 |
Why?
|
| Cannabinoid Receptor Agonists | 2 | 2017 | 6 | 1.020 |
Why?
|
| Methamphetamine | 4 | 2016 | 32 | 1.000 |
Why?
|
| Spatial Behavior | 2 | 2014 | 15 | 0.830 |
Why?
|
| Dopamine Uptake Inhibitors | 4 | 2019 | 34 | 0.790 |
Why?
|
| Amphetamine-Related Disorders | 4 | 2014 | 27 | 0.780 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2022 | 626 | 0.780 |
Why?
|
| Acetaldehyde Dehydrogenase Inhibitors | 1 | 2022 | 5 | 0.770 |
Why?
|
| Double-Blind Method | 11 | 2021 | 1637 | 0.760 |
Why?
|
| Disulfiram | 1 | 2022 | 34 | 0.760 |
Why?
|
| Drug Therapy | 1 | 2022 | 85 | 0.740 |
Why?
|
| Citalopram | 2 | 2014 | 30 | 0.740 |
Why?
|
| Food-Drug Interactions | 1 | 2021 | 10 | 0.740 |
Why?
|
| Alcoholic Beverages | 1 | 2021 | 17 | 0.730 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 2 | 2019 | 26 | 0.710 |
Why?
|
| Blood Pressure | 7 | 2021 | 1369 | 0.710 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2021 | 121 | 0.700 |
Why?
|
| Renal Elimination | 1 | 2020 | 10 | 0.700 |
Why?
|
| Psychomotor Performance | 3 | 2014 | 182 | 0.700 |
Why?
|
| Endocannabinoids | 2 | 2018 | 37 | 0.700 |
Why?
|
| Cannabidiol | 1 | 2020 | 22 | 0.690 |
Why?
|
| Heart Rate | 5 | 2019 | 589 | 0.690 |
Why?
|
| Acetazolamide | 1 | 2020 | 30 | 0.690 |
Why?
|
| Arthralgia | 1 | 2020 | 54 | 0.680 |
Why?
|
| Dog Diseases | 1 | 2020 | 50 | 0.680 |
Why?
|
| Ethanol | 1 | 2021 | 163 | 0.660 |
Why?
|
| Alcoholism | 1 | 2022 | 231 | 0.640 |
Why?
|
| Diuretics | 1 | 2020 | 171 | 0.640 |
Why?
|
| Osteoarthritis | 1 | 2020 | 86 | 0.630 |
Why?
|
| Drug Monitoring | 1 | 2020 | 169 | 0.620 |
Why?
|
| Behavior, Addictive | 3 | 2019 | 58 | 0.610 |
Why?
|
| Polyunsaturated Alkamides | 1 | 2018 | 28 | 0.610 |
Why?
|
| Affect | 3 | 2019 | 158 | 0.610 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2019 | 141 | 0.610 |
Why?
|
| Arachidonic Acids | 1 | 2018 | 29 | 0.600 |
Why?
|
| Amidohydrolases | 1 | 2018 | 23 | 0.600 |
Why?
|
| Comorbidity | 3 | 2022 | 1530 | 0.600 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 3 | 2008 | 18 | 0.550 |
Why?
|
| Dopamine | 11 | 2013 | 283 | 0.550 |
Why?
|
| Quinoxalines | 2 | 2014 | 39 | 0.550 |
Why?
|
| Psychotropic Drugs | 2 | 2012 | 122 | 0.550 |
Why?
|
| Benzazepines | 2 | 2014 | 62 | 0.550 |
Why?
|
| Perindopril | 1 | 2016 | 2 | 0.530 |
Why?
|
| Medication Adherence | 1 | 2020 | 393 | 0.510 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2019 | 1695 | 0.470 |
Why?
|
| Dopamine Agents | 1 | 2013 | 28 | 0.430 |
Why?
|
| Benzhydryl Compounds | 1 | 2014 | 66 | 0.430 |
Why?
|
| Choice Behavior | 1 | 2014 | 132 | 0.420 |
Why?
|
| Male | 35 | 2021 | 61317 | 0.380 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 3 | 2008 | 34 | 0.370 |
Why?
|
| Drug Users | 3 | 2016 | 8 | 0.370 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2019 | 100 | 0.360 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 2 | 2008 | 8 | 0.360 |
Why?
|
| Cannabinoids | 2 | 2018 | 31 | 0.360 |
Why?
|
| Adult | 19 | 2021 | 29554 | 0.360 |
Why?
|
| Anxiety | 2 | 2020 | 959 | 0.360 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 2 | 2008 | 44 | 0.350 |
Why?
|
| Smoking Cessation | 2 | 2023 | 198 | 0.350 |
Why?
|
| Cannabis | 2 | 2020 | 41 | 0.310 |
Why?
|
| Substance-Related Disorders | 1 | 2013 | 455 | 0.310 |
Why?
|
| Administration, Intravenous | 3 | 2019 | 143 | 0.310 |
Why?
|
| Opioid-Related Disorders | 2 | 2022 | 260 | 0.310 |
Why?
|
| Young Adult | 8 | 2021 | 9023 | 0.310 |
Why?
|
| Healthy Volunteers | 2 | 2021 | 134 | 0.300 |
Why?
|
| Bipolar Disorder | 2 | 2023 | 344 | 0.300 |
Why?
|
| Discrimination Learning | 1 | 2008 | 23 | 0.300 |
Why?
|
| Appetitive Behavior | 1 | 2008 | 14 | 0.300 |
Why?
|
| Desipramine | 1 | 2008 | 27 | 0.300 |
Why?
|
| Pilot Projects | 4 | 2021 | 1396 | 0.290 |
Why?
|
| Association Learning | 1 | 2008 | 21 | 0.290 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2021 | 224 | 0.290 |
Why?
|
| Methylphenidate | 1 | 2008 | 58 | 0.290 |
Why?
|
| Macaca mulatta | 4 | 2014 | 491 | 0.280 |
Why?
|
| Animals | 21 | 2020 | 34235 | 0.260 |
Why?
|
| Plasma Membrane Neurotransmitter Transport Proteins | 1 | 2005 | 7 | 0.250 |
Why?
|
| Humans | 32 | 2023 | 124705 | 0.250 |
Why?
|
| Serotonin Agents | 1 | 2005 | 14 | 0.250 |
Why?
|
| Middle Aged | 13 | 2021 | 26884 | 0.250 |
Why?
|
| Acetylcholine | 2 | 2003 | 83 | 0.250 |
Why?
|
| Receptor, Cannabinoid, CB1 | 2 | 2018 | 28 | 0.240 |
Why?
|
| Attention | 2 | 2020 | 202 | 0.240 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2005 | 50 | 0.230 |
Why?
|
| Self Report | 4 | 2022 | 517 | 0.230 |
Why?
|
| Nicotinic Agonists | 4 | 2021 | 45 | 0.220 |
Why?
|
| Conditioning, Operant | 1 | 2004 | 17 | 0.220 |
Why?
|
| Sleep | 2 | 2019 | 344 | 0.220 |
Why?
|
| Aging | 1 | 2011 | 1183 | 0.220 |
Why?
|
| Receptors, Drug | 1 | 2003 | 38 | 0.210 |
Why?
|
| Stress, Psychological | 3 | 2020 | 558 | 0.210 |
Why?
|
| Female | 18 | 2020 | 66577 | 0.210 |
Why?
|
| Brain | 3 | 2021 | 2996 | 0.200 |
Why?
|
| Reaction Time | 3 | 2014 | 175 | 0.200 |
Why?
|
| Prediabetic State | 1 | 2023 | 57 | 0.200 |
Why?
|
| Time Factors | 5 | 2019 | 6323 | 0.190 |
Why?
|
| Rivastigmine | 2 | 2019 | 17 | 0.190 |
Why?
|
| Neuropsychological Tests | 4 | 2021 | 925 | 0.180 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2004 | 1243 | 0.180 |
Why?
|
| Reward | 1 | 2021 | 111 | 0.180 |
Why?
|
| Executive Function | 1 | 2021 | 110 | 0.180 |
Why?
|
| Analysis of Variance | 3 | 2019 | 1021 | 0.170 |
Why?
|
| Yoga | 1 | 2020 | 12 | 0.170 |
Why?
|
| Depressive Disorder, Major | 2 | 2019 | 399 | 0.170 |
Why?
|
| Meditation | 1 | 2020 | 17 | 0.170 |
Why?
|
| Craving | 1 | 2019 | 14 | 0.160 |
Why?
|
| Nicotine | 4 | 2023 | 143 | 0.160 |
Why?
|
| Dogs | 1 | 2020 | 774 | 0.160 |
Why?
|
| Rats | 11 | 2005 | 3728 | 0.160 |
Why?
|
| Single-Blind Method | 1 | 2019 | 237 | 0.160 |
Why?
|
| Nerve Net | 1 | 2021 | 241 | 0.150 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2018 | 9 | 0.150 |
Why?
|
| Schizophrenia | 2 | 2013 | 311 | 0.150 |
Why?
|
| Impulsive Behavior | 2 | 2021 | 145 | 0.150 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 238 | 0.150 |
Why?
|
| Evidence-Based Medicine | 1 | 2022 | 632 | 0.140 |
Why?
|
| Suicide, Attempted | 1 | 2019 | 131 | 0.140 |
Why?
|
| Veterans | 2 | 2022 | 1749 | 0.140 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 129 | 0.140 |
Why?
|
| Varenicline | 2 | 2014 | 14 | 0.140 |
Why?
|
| Recovery of Function | 1 | 2019 | 445 | 0.140 |
Why?
|
| Marijuana Smoking | 1 | 2017 | 31 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 172 | 0.130 |
Why?
|
| Nucleus Accumbens | 5 | 2003 | 54 | 0.130 |
Why?
|
| Adolescent | 7 | 2023 | 19221 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2022 | 12364 | 0.130 |
Why?
|
| Students, Medical | 1 | 2021 | 357 | 0.130 |
Why?
|
| Doxazosin | 1 | 2016 | 28 | 0.130 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 315 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1090 | 0.120 |
Why?
|
| Receptors, Dopamine D3 | 1 | 2015 | 7 | 0.120 |
Why?
|
| Sesquiterpenes | 1 | 2015 | 25 | 0.120 |
Why?
|
| Alkaloids | 1 | 2015 | 35 | 0.120 |
Why?
|
| Benzothiazoles | 1 | 2015 | 30 | 0.120 |
Why?
|
| Central Nervous System Stimulants | 1 | 2016 | 127 | 0.120 |
Why?
|
| Macaca fascicularis | 3 | 2013 | 87 | 0.120 |
Why?
|
| Age Factors | 2 | 2019 | 2807 | 0.120 |
Why?
|
| Models, Biological | 1 | 2020 | 1460 | 0.120 |
Why?
|
| Dopamine Agonists | 1 | 2015 | 79 | 0.120 |
Why?
|
| Inpatients | 1 | 2019 | 495 | 0.120 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 2161 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 224 | 0.120 |
Why?
|
| Nootropic Agents | 1 | 2014 | 27 | 0.110 |
Why?
|
| Phenylcarbamates | 1 | 2013 | 15 | 0.110 |
Why?
|
| Space Perception | 1 | 2014 | 63 | 0.110 |
Why?
|
| Drugs, Investigational | 1 | 2013 | 22 | 0.110 |
Why?
|
| Case-Control Studies | 3 | 2020 | 3293 | 0.110 |
Why?
|
| Drug Interactions | 1 | 2014 | 255 | 0.110 |
Why?
|
| Benzoxazines | 2 | 2003 | 24 | 0.110 |
Why?
|
| Naphthalenes | 2 | 2003 | 37 | 0.110 |
Why?
|
| Headache | 1 | 2014 | 107 | 0.100 |
Why?
|
| Morpholines | 2 | 2003 | 57 | 0.100 |
Why?
|
| Analgesics | 2 | 2003 | 126 | 0.100 |
Why?
|
| Serotonin | 3 | 2005 | 219 | 0.100 |
Why?
|
| Sleep Wake Disorders | 1 | 2014 | 167 | 0.100 |
Why?
|
| Cell Line | 2 | 2008 | 2756 | 0.090 |
Why?
|
| Maze Learning | 1 | 2012 | 128 | 0.090 |
Why?
|
| Phencyclidine | 2 | 2002 | 6 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2015 | 683 | 0.090 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2002 | 94 | 0.090 |
Why?
|
| Hallucinogens | 2 | 2018 | 43 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 4396 | 0.080 |
Why?
|
| Linear Models | 1 | 2012 | 682 | 0.080 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2002 | 148 | 0.080 |
Why?
|
| Weight Gain | 2 | 2023 | 403 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2013 | 553 | 0.080 |
Why?
|
| Calcium Channel Blockers | 2 | 2013 | 115 | 0.080 |
Why?
|
| Reversal Learning | 1 | 2008 | 7 | 0.070 |
Why?
|
| Stereotyped Behavior | 1 | 2008 | 37 | 0.070 |
Why?
|
| Self Administration | 2 | 2019 | 43 | 0.070 |
Why?
|
| Injections, Intramuscular | 1 | 2008 | 194 | 0.070 |
Why?
|
| Corpus Striatum | 3 | 2003 | 92 | 0.070 |
Why?
|
| Stress, Physiological | 2 | 2000 | 256 | 0.070 |
Why?
|
| Mental Recall | 1 | 2008 | 143 | 0.070 |
Why?
|
| Suicidal Ideation | 2 | 2021 | 219 | 0.070 |
Why?
|
| Depression | 1 | 2014 | 1236 | 0.060 |
Why?
|
| Microdialysis | 2 | 2003 | 57 | 0.060 |
Why?
|
| Binding, Competitive | 1 | 2005 | 192 | 0.060 |
Why?
|
| Stereoisomerism | 1 | 2005 | 108 | 0.060 |
Why?
|
| Norepinephrine | 1 | 2005 | 177 | 0.060 |
Why?
|
| Kinetics | 2 | 2005 | 1329 | 0.060 |
Why?
|
| Temperature | 1 | 2005 | 304 | 0.060 |
Why?
|
| Aged | 2 | 2020 | 19830 | 0.060 |
Why?
|
| Membrane Transport Proteins | 1 | 2005 | 176 | 0.050 |
Why?
|
| Receptors, Cannabinoid | 1 | 2003 | 8 | 0.050 |
Why?
|
| Drug Administration Routes | 1 | 2003 | 32 | 0.050 |
Why?
|
| Mice | 1 | 2020 | 17645 | 0.050 |
Why?
|
| Transfection | 1 | 2005 | 1069 | 0.050 |
Why?
|
| Smokers | 1 | 2023 | 39 | 0.050 |
Why?
|
| Biogenic Monoamines | 1 | 2002 | 3 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 410 | 0.050 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2005 | 293 | 0.050 |
Why?
|
| Haloperidol | 2 | 2013 | 23 | 0.050 |
Why?
|
| Mood Disorders | 1 | 2023 | 123 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 3415 | 0.050 |
Why?
|
| Premedication | 1 | 2001 | 42 | 0.050 |
Why?
|
| Receptors, Dopamine | 1 | 2001 | 40 | 0.040 |
Why?
|
| Nicotinic Antagonists | 1 | 2000 | 9 | 0.040 |
Why?
|
| Conditioning, Classical | 1 | 2001 | 54 | 0.040 |
Why?
|
| China | 1 | 2021 | 245 | 0.040 |
Why?
|
| Overweight | 1 | 2023 | 364 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2002 | 293 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 284 | 0.040 |
Why?
|
| Emotions | 1 | 2023 | 358 | 0.040 |
Why?
|
| Visual Analog Scale | 1 | 2019 | 7 | 0.040 |
Why?
|
| Fear | 1 | 2001 | 200 | 0.040 |
Why?
|
| Depressive Disorder | 1 | 2002 | 454 | 0.040 |
Why?
|
| Cerebellum | 1 | 2023 | 415 | 0.040 |
Why?
|
| Aggression | 1 | 2021 | 222 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 1113 | 0.040 |
Why?
|
| Electroshock | 1 | 1998 | 28 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 1113 | 0.040 |
Why?
|
| Foot | 1 | 1998 | 61 | 0.040 |
Why?
|
| Students | 1 | 2020 | 248 | 0.040 |
Why?
|
| Antipsychotic Agents | 2 | 2013 | 370 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 554 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 1 | 2016 | 144 | 0.030 |
Why?
|
| Cognition | 1 | 2021 | 731 | 0.030 |
Why?
|
| Cholesterol, Dietary | 1 | 1996 | 46 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2016 | 110 | 0.030 |
Why?
|
| Smoking | 1 | 2021 | 1047 | 0.030 |
Why?
|
| Child | 3 | 2023 | 24173 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 1998 | 490 | 0.030 |
Why?
|
| Tryptophan | 1 | 1996 | 90 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2015 | 229 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2014 | 3715 | 0.030 |
Why?
|
| Auditory Perception | 1 | 2014 | 37 | 0.030 |
Why?
|
| Acoustic Stimulation | 1 | 2014 | 85 | 0.030 |
Why?
|
| Dietary Fats | 1 | 1996 | 297 | 0.030 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2013 | 19 | 0.030 |
Why?
|
| Visual Perception | 1 | 2014 | 124 | 0.030 |
Why?
|
| Berberine | 1 | 2013 | 8 | 0.030 |
Why?
|
| Monoacylglycerol Lipases | 1 | 2013 | 7 | 0.030 |
Why?
|
| Photic Stimulation | 1 | 2014 | 224 | 0.030 |
Why?
|
| Cholesterol | 1 | 1996 | 539 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 2524 | 0.030 |
Why?
|
| Benzodiazepines | 1 | 2013 | 99 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 2446 | 0.020 |
Why?
|
| Obesity | 1 | 2023 | 2248 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 3560 | 0.020 |
Why?
|
| Mecamylamine | 2 | 2000 | 10 | 0.020 |
Why?
|
| Immobilization | 2 | 2000 | 24 | 0.020 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 2 | 1998 | 9 | 0.020 |
Why?
|
| Phenethylamines | 1 | 2005 | 14 | 0.020 |
Why?
|
| Substantia Nigra | 1 | 2005 | 34 | 0.010 |
Why?
|
| Response Elements | 1 | 2005 | 97 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2005 | 247 | 0.010 |
Why?
|
| Neostriatum | 1 | 2002 | 11 | 0.010 |
Why?
|
| Imipramine | 1 | 2002 | 18 | 0.010 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2002 | 27 | 0.010 |
Why?
|
| Fluoxetine | 1 | 2002 | 43 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 2002 | 271 | 0.010 |
Why?
|
| Dihydro-beta-Erythroidine | 1 | 2000 | 4 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2010 | 4799 | 0.010 |
Why?
|
| Opioid Peptides | 1 | 2000 | 4 | 0.010 |
Why?
|
| Arousal | 1 | 2001 | 81 | 0.010 |
Why?
|
| Ventral Tegmental Area | 1 | 2000 | 46 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 2717 | 0.010 |
Why?
|
| Naloxone | 1 | 2000 | 48 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 3891 | 0.010 |
Why?
|
| Narcotic Antagonists | 1 | 2000 | 109 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 3055 | 0.010 |
Why?
|
| Dihydroxyphenylalanine | 1 | 1998 | 8 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 1998 | 75 | 0.010 |
Why?
|
| Injections | 1 | 1998 | 155 | 0.010 |
Why?
|
| Time | 1 | 1998 | 92 | 0.010 |
Why?
|
| Motor Activity | 1 | 2001 | 522 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1998 | 715 | 0.010 |
Why?
|
| Hydroxylation | 1 | 1996 | 45 | 0.010 |
Why?
|
| Gerbillinae | 1 | 1996 | 55 | 0.010 |
Why?
|